• Phase

    Startup

  • Contact person

    Tobias Erlöv, Co-founder & CEO

  • Email

    tobias.erlov@medqus.com

  • Website
  • Area

    Medtech

Medqus Innovations

Myocardial infarctions and strokes, caused by the rupture of atherosclerotic plaques, are the largest causes of mortality and morbidity in the world. If rupture-prone plaques could be detected before they cause myocardial infarction or stroke, the patients could be treated with lifestyle changes among other things.

In contrast, patients with non-vulnerable plaques would be spared from unnecessary interventions, their inherent risks, side-effects, and costs. However, this is currently not possible.

Atherosclerotic plaques are evaluated by their degree of stenosis (~their size). Unfortunately, size alone does not provide enough information about the risk for plaque rupture. For that, the composition of the plaque is needed.

This is precisely what our innovation offers, a software tool that characterizes the composition of atherosclerotic plaques, based on ultrasound images.

Tobias Erlöv holds a degree in Engineering Physics and a PhD in Biomedical Engineering. He founded Medqus together with Associate Professor Magnus Cinthio and Professor of Cardiology Isabel Goncalves, based on a successful research collaboration dating back more than a decade.

Did you know?

The company name is an acronym for MEDical Quantitative UltraSound, referring to the quantitative analysis of tissue composition enabled by mathematical modelling of the interaction between tissue and ultrasound.

© 2023 Copyright SmiLe Incubator